| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Phosphate load is the most important contributor for vascular calcification in chronic kidney disease. First of all, I explored the treatments which can suppress phosphate-induced calcification and osteoblastic trans-differentiation in vascular smooth muscle cells. I examined the inhibitory effects of a calcimimetic agent R568, sodium thiosulphate, etidronate, 25-hydroxyvitamin D, phosphate restriction and caloric restriction on phosphate-induced calcification and osteoblastic trans-differentiation in vascular smooth muscle cells. The administration of etidronate and phosphate restriction were most effective. However, their effects on the differentiation of monocyte to osteoclastic cell, which is necessary for absorption of calcification, were also suppressive. These results revealed it is difficult that calcification inhibitors, which I examined, regress vascular calcification. In future, the further exploration for candidates of calcification regressor is necessary.
|
